ORGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Organogenesis Holdings Inc (ORGO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and undervalued stock price in pre-market make it an attractive opportunity despite the lack of immediate trading signals.
The MACD is positive and expanding, indicating bullish momentum. However, RSI is neutral at 27.881, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 2.34), suggesting limited downside risk.
The company reported exceptional financial growth in Q4 2025, with revenue up 78.13% YoY, net income up 497.82% YoY, and EPS up 400% YoY. Gross margin also improved to 77.87%. Analysts maintain a Buy rating despite lowering the price target to $8, which still represents significant upside from the current price.
is slightly down (-0.11%) in pre-market trading.
In Q4 2025, Organogenesis demonstrated robust financial growth with revenue of $225.6M (+78.13% YoY), net income of $35.12M (+497.82% YoY), EPS of $0.25 (+400% YoY), and gross margin improvement to 77.87% (+3.17% YoY).
BTIG maintains a Buy rating on ORGO but lowered the price target from $9 to $8, citing a 'new economic reality' despite the company's strong quarterly performance.
